PubMed

Attenuation and efficacy of human parainfluenza virus type 1 (HPIV1) vaccine candidates containing stabilized mutations in the P/C and L genes.

Bartlett EJ, Castaño A, Surman SR, Collins PL, Skiadopoulos MH, Murphy BR.

Virol J. 2007 Jul 2;4:67.PMID: 17605811 [PubMed - indexed for MEDLINE]Related articlesFree article

Introducing point and deletion mutations into the P/C gene of human parainfluenza virus type 1 (HPIV1) by reverse genetics generates attenuated and efficacious vaccine candidates.

Bartlett EJ, Amaro-Carambot E, Surman SR, Collins PL, Murphy BR, Skiadopoulos MH.

Vaccine. 2006 Mar 24;24(14):2674-84. Epub 2005 Nov 15.PMID: 16364511 [PubMed - indexed for MEDLINE]Related articles

Human parainfluenza virus type I (HPIV1) vaccine candidates designed by reverse genetics are attenuated and efficacious in African green monkeys.

Bartlett EJ, Amaro-Carambot E, Surman SR, Newman JT, Collins PL, Murphy BR, Skiadopoulos MH.

Vaccine. 2005 Sep 7;23(38):4631-46.PMID: 15951066 [PubMed - indexed for MEDLINE]Related articles

A novel human parainfluenza virus type 1 (HPIV1) with separated P and C genes is useful for generating C gene mutants for evaluation as live-attenuated virus vaccine candidates.

Bartlett EJ, Cruz AM, Boonyaratanakornkit J, Esker J, Castaño A, Skiadopoulos MH, Collins PL, Murphy BR, Schmidt AC.

Vaccine. 2010 Jan 8;28(3):767-79. Epub 2009 Oct 24.PMID: 19857454 [PubMed - indexed for MEDLINE]Related articles

Generation of recombinant human parainfluenza virus type 1 vaccine candidates by importation of temperature-sensitive and attenuating mutations from heterologous paramyxoviruses.

Newman JT, Riggs JM, Surman SR, McAuliffe JM, Mulaikal TA, Collins PL, Murphy BR, Skiadopoulos MH.

J Virol. 2004 Feb;78(4):2017-28.PMID: 14747566 [PubMed - indexed for MEDLINE]Related articlesFree article

Attenuating mutations in the P/C gene of human parainfluenza virus type 1 (HPIV1) vaccine candidates abrogate the inhibition of both induction and signaling of type I interferon (IFN) by wild-type HPIV1.

Van Cleve W, Amaro-Carambot E, Surman SR, Bekisz J, Collins PL, Zoon KC, Murphy BR, Skiadopoulos MH, Bartlett EJ.

Virology. 2006 Aug 15;352(1):61-73. Epub 2006 Jun 5.PMID: 16750233 [PubMed - indexed for MEDLINE]Related articles

Human parainfluenza virus type 1 C proteins are nonessential proteins that inhibit the host interferon and apoptotic responses and are required for efficient replication in nonhuman primates.

Bartlett EJ, Cruz AM, Esker J, Castaño A, Schomacker H, Surman SR, Hennessey M, Boonyaratanakornkit J, Pickles RJ, Collins PL, Murphy BR, Schmidt AC.

J Virol. 2008 Sep;82(18):8965-77. Epub 2008 Jul 9.PMID: 18614629 [PubMed - indexed for MEDLINE]Related articlesFree article

The recombinant chimeric human parainfluenza virus type 1 vaccine candidate, rHPIV3-1cp45, is attenuated, immunogenic, and protective in African green monkeys.

Skiadopoulos MH, Tatem JM, Surman SR, Mitcho Y, Wu SL, Elkins WR, Murphy BR.

Vaccine. 2002 Mar 15;20(13-14):1846-52.PMID: 11906774 [PubMed - indexed for MEDLINE]Related articles

Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone.

Schmidt AC, Wenzke DR, McAuliffe JM, St Claire M, Elkins WR, Murphy BR, Collins PL.

J Virol. 2002 Feb;76(3):1089-99.PMID: 11773385 [PubMed - indexed for MEDLINE]Related articlesFree article

Role of interferon in the replication of human parainfluenza virus type 1 wild type and mutant viruses in human ciliated airway epithelium.

Bartlett EJ, Hennessey M, Skiadopoulos MH, Schmidt AC, Collins PL, Murphy BR, Pickles RJ.

J Virol. 2008 Aug;82(16):8059-70. Epub 2008 Jun 4.PMID: 18524813 [PubMed - indexed for MEDLINE]Related articlesFree article

Codon substitution mutations at two positions in the L polymerase protein of human parainfluenza virus type 1 yield viruses with a spectrum of attenuation in vivo and increased phenotypic stability in vitro.

McAuliffe JM, Surman SR, Newman JT, Riggs JM, Collins PL, Murphy BR, Skiadopoulos MH.

J Virol. 2004 Feb;78(4):2029-36.PMID: 14747567 [PubMed - indexed for MEDLINE]Related articlesFree article

Recombinant human parainfluenza virus type 2 vaccine candidates containing a 3' genomic promoter mutation and L polymerase mutations are attenuated and protective in non-human primates.

Nolan SM, Skiadopoulos MH, Bradley K, Kim OS, Bier S, Amaro-Carambot E, Surman SR, Davis S, St Claire M, Elkins R, Collins PL, Murphy BR, Schaap-Nutt A.

Vaccine. 2007 Aug 21;25(34):6409-22. Epub 2007 Jul 3.PMID: 17658669 [PubMed - indexed for MEDLINE]Related articlesFree article

Replacement of the ectodomains of the hemagglutinin-neuraminidase and fusion glycoproteins of recombinant parainfluenza virus type 3 (PIV3) with their counterparts from PIV2 yields attenuated PIV2 vaccine candidates.

Tao T, Skiadopoulos MH, Davoodi F, Riggs JM, Collins PL, Murphy BR.

J Virol. 2000 Jul;74(14):6448-58.PMID: 10864657 [PubMed - indexed for MEDLINE]Related articlesFree article

Sequential addition of temperature-sensitive missense mutations into the PB2 gene of influenza A transfectant viruses can effect an increase in temperature sensitivity and attenuation and permits the rational design of a genetically engineered live influenza A virus vaccine.

Subbarao EK, Park EJ, Lawson CM, Chen AY, Murphy BR.

J Virol. 1995 Oct;69(10):5969-77.PMID: 7666501 [PubMed - indexed for MEDLINE]Related articlesFree article

Attenuation of the recombinant human parainfluenza virus type 3 cp45 candidate vaccine virus is augmented by importation of the respiratory syncytial virus cpts530 L polymerase mutation.

Skiadopoulos MH, Surman SR, St Claire M, Elkins WR, Collins PL, Murphy BR.

Virology. 1999 Jul 20;260(1):125-35.PMID: 10405364 [PubMed - indexed for MEDLINE]Related articles

Sendai virus, a murine parainfluenza virus type 1, replicates to a level similar to human PIV1 in the upper and lower respiratory tract of African green monkeys and chimpanzees.

Skiadopoulos MH, Surman SR, Riggs JM, Elkins WR, St Claire M, Nishio M, Garcin D, Kolakofsky D, Collins PL, Murphy BR.

Virology. 2002 May 25;297(1):153-60.PMID: 12083845 [PubMed - indexed for MEDLINE]Related articles

Replacement of the F and G proteins of respiratory syncytial virus (RSV) subgroup A with those of subgroup B generates chimeric live attenuated RSV subgroup B vaccine candidates.

Whitehead SS, Hill MG, Firestone CY, St Claire M, Elkins WR, Murphy BR, Collins PL.

J Virol. 1999 Dec;73(12):9773-80.PMID: 10559287 [PubMed - indexed for MEDLINE]Related articlesFree article

A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin-neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animals immune to PIV3.

Tao T, Davoodi F, Cho CJ, Skiadopoulos MH, Durbin AP, Collins PL, Murphy BR.

Vaccine. 2000 Jan 31;18(14):1359-66.PMID: 10618533 [PubMed - indexed for MEDLINE]Related articles

Live-attenuated intranasal parainfluenza virus type 2 vaccine candidates developed by reverse genetics containing L polymerase protein mutations imported from heterologous paramyxoviruses.

Nolan SM, Surman SR, Amaro-Carambot E, Collins PL, Murphy BR, Skiadopoulos MH.

Vaccine. 2005 Sep 15;23(39):4765-74.PMID: 15964103 [PubMed - indexed for MEDLINE]Related articles

Identification of mutations contributing to the temperature-sensitive, cold-adapted, and attenuation phenotypes of the live-attenuated cold-passage 45 (cp45) human parainfluenza virus 3 candidate vaccine.

Skiadopoulos MH, Surman S, Tatem JM, Paschalis M, Wu SL, Udem SA, Durbin AP, Collins PL, Murphy BR.

J Virol. 1999 Feb;73(2):1374-81.PMID: 9882342 [PubMed - indexed for MEDLINE]Related articlesFree article